Sublocade vs. Brixadi: What's the Difference?

If you've been managing opioid use disorder with daily sublingual buprenorphine (Suboxone, Subutex, or a generic film or tablet) and are looking for something that doesn't require thinking about medication every day, you've likely come across two names: Sublocade and Brixadi. Both are long-acting, injectable forms of buprenorphine, and both can significantly reduce the burden of daily dosing. But they aren't identical products, and understanding how they differ can help you have a more informed conversation with your provider about which one might fit your life better.

What Sublocade and Brixadi Have in Common

Sublocade and Brixadi are both extended-release formulations of buprenorphine, and both are FDA-approved specifically for moderate-to-severe opioid use disorder in adults. They share several important features. Both are injected subcutaneously, meaning under the skin — never into a vein (IV) or muscle (IM). This matters clinically: because the medication forms a depot under the skin that releases buprenorphine slowly over time, injecting it the wrong way can cause serious harm.

Both medications also start from transmucosal (sublingual, or under-the-tongue) buprenorphine. Under current FDA labeling, Sublocade can be started after a single dose of transmucosal buprenorphine followed by a one-hour observation period, or in patients already taking buprenorphine. Brixadi's weekly injection can be started after a 4mg transmucosal test dose in people not currently taking buprenorphine, while Brixadi's monthly injection is used for patients who are already on buprenorphine. That first sublingual dose isn't a formality — it confirms your body tolerates buprenorphine and helps your provider choose a safe starting dose.

Both are provider-administered only. Neither Sublocade nor Brixadi is a take-home injection or something you'd draw up and inject yourself; a clinician gives the shot at an office visit. Because of this, both products are distributed under a federal Risk Evaluation and Mitigation Strategy (REMS) program rather than through a standard retail pharmacy.

Brixadi vs. Sublocade at a Glance

The difference between Brixadi and Sublocade comes down to dosing interval, how treatment starts, and a few practical details such as injection sites and storage.

Dosing Schedule Differences

Sublocade's initiation process is structured and sequential. It begins with a single 4mg sublingual test dose of buprenorphine, which you take under observation for one hour to confirm tolerability. From there, you receive two loading injections of 300mg each, with the second dose given anywhere from one week to one month after the first. After the loading phase, you move to a maintenance dose of 100mg injected monthly, with a minimum of 26 days required between injections. If 100mg isn't providing an adequate response, a 300mg monthly maintenance dose is available as an option.

Brixadi works differently in that it isn't a single dosing path — it comes in two distinct formulations, and you and your provider choose which fits best. The weekly formulation is dosed at 8mg, 16mg, 24mg, or 32mg, given every 7 days. The monthly formulation is dosed at 64mg, 96mg, or 128mg, given every 28 days. This built-in flexibility means Brixadi can be adjusted to a more frequent, lower-per-dose schedule or a less frequent, higher-per-dose schedule, potentially even switching between the two over the course of treatment.

Side Effects and Safety

Because both injections contain buprenorphine, many side effects are similar to those of daily Suboxone. In clinical trials, the most common side effects of Sublocade included constipation, headache, nausea, vomiting, itching or pain at the injection site, fatigue, and increased liver enzymes. For Brixadi, the most common were injection-site pain, redness, and itching, along with headache, constipation, nausea, trouble sleeping, and urinary tract infection.

• Boxed warning (both): serious harm or death could result if the medication is injected into a vein. This is why both are given only by a healthcare provider in a certified setting.
• Injection-site reactions: usually mild and temporary. Brixadi's weekly injection sites are rotated; a small lump under the skin is expected with either product as the depot forms.
• Sedation and breathing: combining buprenorphine with alcohol, benzodiazepines, or other sedatives increases the risk of dangerous sedation and slowed breathing. Tell your provider about every medication and substance you use.
• Liver health and pregnancy: your provider will review liver function, pregnancy status, and other conditions before choosing an injection.

Neither injection should be used by people who are allergic to buprenorphine or the product's other ingredients. Your provider will go over the full safety information for whichever product you choose.

Switching From Daily Suboxone to an Injection

Many patients move to a long-acting injection after doing well on daily Suboxone or generic buprenorphine/naloxone. For Brixadi, the FDA label provides a direct conversion from your current daily sublingual dose:

For Sublocade, patients who are already taking buprenorphine move into the standard schedule of two 300mg loading injections followed by monthly maintenance. Switching between Sublocade and Brixadi is also possible, but the timing depends on your current dose and how you've responded, so it's planned individually with your provider. If you're not yet on buprenorphine, the first step is usually starting Suboxone online or in person, then discussing an injection once you're comfortable.

Sublocade vs. Brixadi vs. Daily Suboxone

All three contain buprenorphine. The main differences are how often you take it and who gives it.

Daily Suboxone remains a highly effective option, and many patients stay on it long term. An injection can make sense if remembering daily doses is hard, you want more privacy at home, or you want steadier medication levels. See why some patients consider a buprenorphine injection and how long an injection lasts.

Getting Started on Either Medication

Because both Sublocade and Brixadi are only administered by a healthcare provider, you can't fill a prescription for either one at a regular retail pharmacy and take it home. Each medication is distributed exclusively through its own REMS program, which restricts distribution to certified healthcare settings and pharmacies that, in turn, dispense the medication only to a provider for administration — never directly to a patient. In practice, this means every dose is given as part of a clinical visit, whether that's your first loading injection or a routine monthly follow-up. If you're starting treatment, your provider will first confirm you tolerate sublingual buprenorphine, then schedule the injection visit(s) needed to begin either product.

Getting a Sublocade or Brixadi injection at Acorn TeleMAT: your first consultation can happen by phone from anywhere in California. Your provider reviews your history and current dose, orders the injection, and sends it to a specialty pharmacy while helping coordinate insurance approval. Follow-up visits can often be done by telehealth between injections. The $199 Care Package covers up to 4 visits in 30 days, which can be useful while you transition to an injection.

Cost, Insurance, and Savings Programs

Sublocade and Brixadi are typically billed through your insurance and shipped from a specialty pharmacy to the treating office. Your out-of-pocket cost depends on your plan's coverage, prior authorization, deductible, and copay.

• Sublocade Copay Assistance Program: for patients with private (commercial) insurance; it covers the medication only, not office visits. Patients with government insurance such as Medicare, Medi-Cal/Medicaid, VA, or TRICARE are not eligible.
• Brixadi copay program: eligible commercially insured patients may pay as little as $0 per injection when their plan covers Brixadi. Patients with state or federal coverage, including Medicare and Medi-Cal/Medicaid, are excluded.
• Visit fees are separate: self-pay visits at Acorn TeleMAT are $99 each, or $199 for up to 4 visits within 30 days. Medication and lab costs are not included.

Program terms change, so confirm current eligibility with the manufacturer. For a full breakdown, see Suboxone cost and insurance in California.

Which One Is Right for You?

There's no single "better" option between Sublocade and Brixadi — the right fit depends on a few personal and clinical factors. One is simply how you feel about visit frequency: some patients prefer the lower visit burden of a monthly injection, while others like the more frequent check-ins and dose flexibility that a weekly schedule provides, at least initially. Another factor is where you are in treatment — Sublocade's structured loading-dose approach was studied specifically as a path from daily sublingual buprenorphine into monthly dosing, while Brixadi's weekly-or-monthly design offers more flexibility to titrate a dose up or down as your needs change. Your prior treatment history, how you've responded to buprenorphine so far, and your provider's clinical judgment all factor into the decision as well. Rather than deciding on your own, this is a conversation to have directly with your provider, who can weigh these factors against your specific history and goals.

This article is for general educational purposes and isn't a substitute for individualized medical advice. Your treatment plan should be developed with your own provider based on your specific health history.